Trastuzumab deruxtecan
- Generic Name
- Trastuzumab deruxtecan
- Brand Names
- Enhertu
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1826843-81-5
- Unique Ingredient Identifier
- 5384HK7574
- Background
Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...
- Indication
In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...
- Associated Conditions
- Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer
- Associated Therapies
- -
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 165
- Registration Number
- NCT06172127
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario de Basurto, Bilbao, Spain
🇪🇸Hospital Provincial de Castellón, Castello de la Plana, Spain
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 252
- Registration Number
- NCT06102824
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Jeeyun Lee
- Target Recruit Count
- 61
- Registration Number
- NCT06085755
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06058988
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
- Conditions
- Interventions
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 257
- Registration Number
- NCT05993234
- Locations
- 🇧🇪
Imelda vzw, Bonheiden, Belgium
🇧🇪UZ Brussel, Jette, Belgium
🇩🇪KRH Klinikum Siloah, Hannover, Germany
Basket Study for Oligo-metastatic Breast Cancer
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 72
- Registration Number
- NCT05982678
- Locations
- 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Netherlands
Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- University of Southampton
- Target Recruit Count
- 25
- Registration Number
- NCT05965479
- Locations
- 🇬🇧
Royal Surrey NHS Foundation Trust, Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
🇬🇧University Hospitals Coventry and Warwickshire, University Hospital Coventry, Coventry, Warwickshire, United Kingdom
🇬🇧Belfast Health and Social Care Trust, Belfast City Hospital, Belfast, United Kingdom
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 69
- Registration Number
- NCT05953168
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 250
- Registration Number
- NCT05950945
- Locations
- 🇧🇷
Catarina Pesquisa Clinica, Santa Catarina, Brazil
🇧🇷CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo André, Brazil
🇧🇪Universitair Ziekenhuis Brussel, Bruxelles, Belgium
DESTINY Breast Respond HER2-low Europe
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 1350
- Registration Number
- NCT05945732
- Locations
- 🇦🇹
Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria
🇦🇹LKH Hochsteiermark-Leoben, Leoben, Austria
🇧🇪Chirec Delta Hospital, Auderghem, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.